Tests an eye implant with a new lens against eye drops in cataract patients
Tests a bimatoprost eye implant with a lens against timolol drops in glaucoma patients.
Plain-language title generated from the registry record
Registry title: Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
Key facts
- Where
- Houston, United StatesSee the site
- Phase
- Phase 3
Where in United States
- Houston Eye AssociatesHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- SpyGlass Pharma, Inc.
- Trial code
- NCT07218783
- Record updated
- 20 October 2025
- Original description
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.Read full original descriptionShow less
A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,
This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.
Inclusion: Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension; Planned removal of cataract; Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception.
Exclusion: Uncontrolled systemic disease; History of incisional/refractive corneal surgery; History of incisional glaucoma surgery or intraocular injections; Other ocular diseases, pathology, or conditions; Any glaucoma diagnosis other than OHT, open-angle, pseudoexfoliative, or pigmentary glaucoma.